Dr. Mark D. Harris, M.D.
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Medical school
- Tufts University School of Medicine (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 695
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Tufts University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
NC license 200100549
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Novant Health New Hanover Regional Medical Center Wilmington, NC
Medical groups
- Carolina Arthritis Associates PA (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 695
- Services billed
- 296,175
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, tocilizumab, 1 mg | 114,560 | 32 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 39,400 | 102 |
| Injection, golimumab, 1 mg, for intravenous use | 32,500 | 55 |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 31,600 | 14 |
| Injection, infliximab, excludes biosimilar, 10 mg | 5,710 | 40 |
| Injection, denosumab, 1 mg | 3,840 | 39 |
| Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 2,300 | 21 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,176 | 427 |
| Measurement c-reactive protein for detection of infection or inflammation | 1,134 | 416 |
| Administration of chemotherapy into vein, 1 hour or less | 1,090 | 240 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 11 payments worth $235 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $59.24 |
|---|---|
| AbbVie Inc. | $28.25 |
| Radius Health, Inc. | $25.85 |
| Organon LLC | $22.80 |
| Actelion Pharmaceuticals US, Inc. | $22.11 |
| Novartis Pharmaceuticals Corporation | $21.21 |
| Fresenius Kabi USA, LLC | $20.50 |
| UCB, Inc. | $19.93 |
| Food and Beverage | $235 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $9,178 in research payments for these studies, mostly to the institutions running them.
- A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome
Novartis Pharmaceuticals Corporation - A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Imm…
Argenx US, Inc. - A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1)
Novartis Pharmaceuticals Corporation - A Study of Baricitinib in Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT04086745
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.